Skip to main content

In Brief This Week: Bio-Rad Laboratories; Exact Sciences; Thermo Fisher; BD; Sigma-Aldrich; Diagenode; Promega; SAP, MolecularHealth; Gen9

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said in a filing with the US Securities and Exchange Commission this week that the total consideration for its acquisition of Propel Labs' cell sorting system was $49.6 million. The firm announced the acquisition a couple of weeks ago but had said at the time that the purchase price was undisclosed.

In its Form 10-Q filed earlier this week Bio-Rad said that it paid $5 million in cash at the closing date with $44.6 million in contingent consideration potentially payable to Propel Labs' shareholders. That contingent consideration consists of $19.9 million in development milestones and $24.7 million in sales milestones.


Exact Sciences this week said that it has completed patient enrollment for its DeeP-C pivotal trial for colorectal cancer screening. The trial has enrolled more than 12,700 patients and its results are expected to form the basis of Exact Sciences' Pre-Market Approval application with the US Food and Drug Administration for its Cologuard test.

During its recent third-quarter conference call CFO Maneesh Arora said that the DeeP-C trial would close on Nov. 15, and the company remains on track for submitting Cologuard for FDA approval.


Thermo Fisher Scientific opened a new facility in Suzhou, China for manufacturing life science consumables and equipment. Plastic labware and consumables, such as sample prep products and filterware, as well as laboratory refrigerators, freezers, incubators, and centrifuges will be manufactured at the new facility, which will follow the best global and local manufacturing practices, including ISO9001, ISO14001, and ISO13485 standards.


Becton Dickinson said this week that the Diagenode Respiratory Flu A/B primers and probes kit that runs on its BD Max System has received the CE Mark and has been launched in Europe.


Sigma-Aldrich's board has approved a quarterly cash dividend of $.20 per share, payable on Dec. 14 to shareholders of record on Nov. 30.


Promega has opened a new facility in Shanghai for its China operations. The new site for Shanghai Promega Biological Products replaces an existing molecular biology reagent production site and provides additional R&D and cGMP manufacturing capabilities, said Promega.


SAP and MolecularHealth are teaming up on a personalized medicine informatics platform for oncologists. The system will utilize SAP's HANA platform and will "translate terabytes of clinical, molecular and drug data into real-time and effective treatment choices for each individual patient," the firms said.


Gen9 has named five winners of its inaugural G-Prize contest. The winners collectively will receive more than 1 million base pairs of DNA manufactured with Gen9's next-generation gene synthesis technology. The winners include Tanja Kortemme of the University of California, San Francisco; Sarel Fleishman of the Weizmann Institute; Alfonso Jaramillo of the Institute of Systems & Synthetic Biology and Xavier Duportet of the Massachusetts Institute of Technology; and Lynn Rothschild of NASA.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.